Immunotherapy is now part of standard of care for some types of triple negative breast cancer, with much more research ongoing.
This year we’ve seen some encouraging news with approvals of a targeted therapy and an immunotherapy for triple negative breast cancer.
Cancer research stories worth following this spring include a study on the benefits of one type of immune system therapy for patients with metastatic triple negative breast cancer.
Cancer research stories worth following this winter include a possible new use for an existing drug to prevent metastasis in triple negative breast cancer.
Cancer research stories worth following this spring include a potential new combination treatment for HER2-positive breast cancer and evidence that a gene assay may help breast cancer patients avoid unnecessary chemotherapy treatment.
Cancer research stories worth following this winter include an experimental targeted therapy for metastatic triple negative breast cancer and a study on how the financial toxicity of cancer treatment affects physical health and survival.
Research findings presented at the 2015 San Antonio Breast Cancer Symposium may preview an era in which breast cancer treatments will be tailored to each patient.
What’s exciting in cancer research right now? In this post, I’ll review several of the recent stories that seem to have the great potential impact, at least from my perspective, and that I know I’ll want to follow as they develop further.
In “adaptive” clinical trial design, the goal is to identify as rapidly as possible new drug therapies that show a likelihood of being successful in specific patient populations.
My top five takeaways from the 2013 San Antonio Breast Cancer Symposium.